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Masato Ohtsuka1*, Hiromi Miura1, Keiji Mochida2, Michiko Hirose2, Ayumi Hasegawa2, Atsuo Ogura2,3,
Ryuta Mizutani4, Minoru Kimura1, Ayako Isotani5, Masahito Ikawa6, Masahiro Sato7 and
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Background: The pronuclear injection (PI) is the simplest and widely used method to generate transgenic (Tg)
mice. Unfortunately, PI-based Tg mice show uncertain transgene expression due to random transgene insertion
in the genome, usually with multiple copies. Thus, typically at least three or more Tg lines are produced by
injecting over 200 zygotes and the best line/s among them are selected through laborious screening steps. Recently,
we developed technologies using Cre-loxP system that allow targeted insertion of single-copy transgene into a
predetermined locus through PI. We termed the method as PI-based Targeted Transgenesis (PITT). A similar
method using PhiC31-attP/B system was reported subsequently.
Results: Here, we developed an improved-PITT (i-PITT) method by combining Cre-loxP, PhiC31-attP/B and FLP-FRT
systems directly under C57BL/6N inbred strain, unlike the mixed strain used in previous reports. The targeted Tg
efficiency in the i-PITT typically ranged from 10 to 30%, with 47 and 62% in two of the sessions, which is by-far
the best Tg rate reported. Furthermore, the system could generate multiple Tg mice simultaneously. We demonstrate
that injection of up to three different Tg cassettes in a single injection session into as less as 181 zygotes resulted in
production of all three separate Tg DNA containing targeted Tg mice.
Conclusions: The i-PITT system offers several advantages compared to previous methods: multiplexing
capability (i-PITT is the only targeted-transgenic method that is proven to generate multiple different transgenic
lines simultaneously), very high efficiency of targeted-transgenesis (up to 62%), significantly reduces animal
numbers in mouse-transgenesis and the system is developed under C57BL/6N strain, the most commonly used
pure genetic background. Further, the i-PITT system is freely accessible to scientific community.
Keywords: Transgenic mouse, Pronuclear injection-based targeted transgenesis, Cre-loxP, PhiC31-attP/B, FLP-FRT,
Rosa26, Transportation of the cauda epididymidesBackground
Transgenic (Tg) mice have been extensively used for
in vivo analysis of gene function and generation of hu-
man disease models. Since generation of the first Tg
mice was reported by Gordon et al. in 1980, who per-
formed pronuclear injection (PI) of purified DNA into
zygotes, PI-mediated transgenesis has been the most* Correspondence: masato@is.icc.u-tokai.ac.jp
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unless otherwise stated.common method for more than 30 years [1-3]. In gen-
eral, for obtaining several Tg mouse lines harboring a
specific transgene, it typically requires approximately
200 or more eggs. Unfortunately, the PI-mediated trans-
genesis is often associated with wide variability in the
level and pattern of transgene expression, which causes
phenotypic variability among individual Tg lines, prob-
ably due to the random nature of copy number, config-
uration, and insertion site of the transgene. Due to such
variability in transgene expression, researchers need to
extensively screen various lines and choose the mostl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pression, which is a very laborious and time-consuming
task [4].
To overcome the pitfalls associated with random trans-
genesis, single-copy insertion of a transgene into a prede-
termined genomic locus can be accomplished using
Embryonic Stem (ES) cell-mediated gene targeting,
which is the gold-standard for generation of targeted Tg
mice [4]. However, this approach is laborious, expensive,
and time-consuming when compared to PI-based trans-
genesis. Strategies using recombinase- or integrase-based
targeted insertion through PI have been recently de-
scribed by us and others [4-7]. We termed this technology
as “Pronuclear Injection-based Targeted Transgenesis
(PITT). The PITT system requires a ‘seed mice strain’
containing a suitable landing pad at a predetermined
genomic locus as an embryo donor for PI. The method
requires, in its initial stage, to establish the seed mouse
by targeted insertion of the landing pad via conven-
tional ES cell-based gene targeting approach. Such an
established mouse line serves as a “seed” strain, from
which Tg mice harboring the DNA of interest (DOI)
are generated by injection of donor vector into zygotes
along with DNA/mRNA for recombinase or integrase.
For performing targeted insertion of DOI using a seed
strain, we and another group used Cre-loxP recombin-
ation system [6,7], while a third group used PhiC31
integrase system [5].
Despite the advantages of PITT approach compared to
traditional methods, its full potential is not discovered yet,
because the available methods are only single-enzyme
based PITT versions. We hypothesized that further im-
proving of the PITT by combining multiple recombinase-
integrase systems, the method can be made more efficient,
versatile and capable of multiplexing. Specifically, we an-
ticipated that such a strategy should make the PITT
method able to rapidly generate multiple different trans-
genic lines simultaneously, that are targeted precisely to
the same genomic location. This would ultimately facili-
tate many areas of biomedical research that depend on
rapid generation of multiple, reliable transgenic mice since
it would address the major constraints such as time, costs
and variable efficiencies associated with the use of ES
cell-based targeted transgenesis approach while taking
care of several pitfalls associated with random transgen-
esis approaches. Therefore, in this report we further im-
proved the technique by creating the next generation seed
mouse with a combination of elements including mutant
loxP, mutant FRT, and attP sites at the Rosa26 locus.
We termed the new seed mouse as TOKMO-3 (Tokai
Masato Ohtsuka no.3) and the method as improved-
PITT (i-PITT). This system adds many new features
and capabilities to the previously described PITT, and
to the targeted transgenesis approaches in general.These features are: 1) The i-PITT method enables the
use of any of the three insertion systems, viz. Cre, PhiC31
or FLP, or combinations, for inserting the Tg cassettes. 2)
Simultaneous use of two systems, for e.g., Cre-loxP-medi-
ated recombination and PhiC31 integration, significantly
enhances the targeted insertion efficiency. 3) Many Tg
DOI constructs can be co-injected to produce Tg lines
for each of the constructs injected. 4) The multiplexing
capability allows the generation of transgenic lines with
70 zygotes per donor Tg construct or less (three separate
DOI containing Tg lines were produced in an injection
session using less than 200 zygotes). 5) The new seed
mouse is under the C57BL/6N genetic background, which
is widely used as a standard strain by the scientific
community, including the International Knockout Mouse
Consortium (IKMC) [8]. Recently there have been remark-
able advances in knockout technology using CRISPR/Cas9
system in which multiple gene knockouts can be made
in a single microinjection session. The i-PITT method
described here offers the advantage of creating multiple
Tg models in a single experimental session and thus serves
as an analogous tool for multiplexing in Tg technology
similar to CRISPR/Cas9 tool for KO technology.
Results
i-PITT Strategy
The overall scheme of i-PITT is illustrated in Figure 1.
A new PITT seed mouse (TOKMO-3) under C57BL/6N
genetic background was engineered by inserting a land-
ing pad containing loxP derivatives (JT15 and lox2272),
attP, and FRT derivatives (F14, F15 and FRT-L) into the
Rosa26 locus through ES cell-based targeting. A donor
vector carrying tdTomato-pA, loxP derivatives (JTZ17
and lox2272), attB, and FRT derivatives (F14, F15 and
FRT-R) was designed to perform site-specific insertion of
a transgene (e.g. “tdTomato-pA” in Figure 1). The trans-
gene flanked by the F14 and F15 sites in the donor vector
was inserted into target locus of fertilized eggs via i-PITT
(Figure 1 and Additional file 1: Figure S1) that offers op-
tions for any of the three enzymes Cre, PhiC31 or FLP to
choose for targeted insertion. The resulting embryos will
exhibit “targeted insertion with extra sequence (TIex)” al-
lele. The strategy is designed in such way that the extra se-
quences will be flanked by F14 and F15 elements which
enable the removal of extra sequences by breeding with
FLP mouse. This results in cleanly inserted transgene
flanked by only the F14 and F15 sites (“TIΔex” allele).
Although the structures of TIex allele differ among the
site-specific insertion systems employed (e.g. TIex allele
1 and 2; Figure 1), the structure of final TIΔex alleles
generated will be identical in all the strategies. Com-
bination of mutant loxPs (JT15/JTZ17 and lox2272)
was same as in our original PITT system [6]. Among
the multitude of mutant FRT sites reported previously,
Figure 1 Schematic of PITT-mediated targeted insertion using the new seed mice, TOKOM-3. Cre-PITT (via mutant loxP sites) and PhiC31-PITT
(via attB/P site) confer insertion of the donor vector containing. DNA Of Interest (DOI), into a target site in the genome, to generate TIex allele 1 or
2 respectively. DOI shown in this example is tdTomato-poly(A) cassette in this figure. Introduction of FLP removes extra sequence in the TIex
allele 1 and 4, resulting in generation of TIΔex allele. See Additional file 1: Figures S1, S3 and S4 for other possible outcomes recombination.
GTNOP: a cassette containing “eGFP-T2A-Neomycin resistant gene-hOCT4-PolyA”.
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R (inverted repeat variant), since F14/F15 pairing was
known to be incompatible [9] and thus we anticipated
that combination of the spacer variants and the inverted
repeat variant would show high recombination efficiency
similar to JT15/JTZ17 and lox2272 combinations for the
Cre-loxP system [6]. The targeted allele also contains a
43-bp fragment corresponding to human OCT4 gene se-
quence [described in Hockemeyer et al. [10]] that can
serve as a zinc finger nuclease target to aid in insertion of
additional sequences for future needs, but the component
is not tested yet.
Verification of landing pad insertion in ES cells
To confirm that three kinds of landing pads work in the
genomic context, we first established an ES cell clone
(termed #BDU7) that contains mutant loxP, mutant FRT
and attP sites at the Rosa26 locus. The #BDU7 was
then transfected with a pBDR donor vector carrying a
promoter-less tdTomato gene, the recombinase (iCre
and/or FLPo) and/or integrase (PhiC31o) expression
vectors. The tdTomato expression will be driven by en-
dogenous Rosa26 promoter only if a correct insertion
of the cassette at the target locus occurs. The red
fluorescence in successfully targeted cells was detected
by FACS analysis. Two days after transfection, approximately1% of cells were positive for tdTomato fluorescence when
iCre- or PhiC31o-expression vector (5 μg per experiment)
was used (Figure 2A), but when FLPo-expression vector was
used, only a few cells showed tdTomato fluorescence
(Figure 2A). Notably, the percentage of fluorescent
cells increased when any two expression vectors (iCre
and PhiC31o or iCre and FLPo or PhiC31o and FLPo
expression vectors; all 2.5 μg each) were co-transfected
(Figure 2B and Additional file 1: Figure S2B). We then
tested if inclusion of six copies of tandem repeats of
recombination/integration sites in the donor vector
would increase the insertion efficiency (Additional file 1:
Figure S2A and S2B) and found that it was slightly im-
proved (0.90% to 1.21%) in the Cre-loxP-based system,
when 6xJTZ17 was included in a donor vector. No obvi-
ous improvement was noticed in the PhiC31-based system
(Additional file 1: Figure S2B).
These results indicated that 1) the landing pad archi-
tecture we designed worked as expected, and 2) the Cre-
based and PhiC31-based gene insertion systems showed
comparable targeted insertion efficiencies, while overall
efficiency of the FLP-based system was relatively poor
compared to PhiC31- and Cre-based systems, 3) the
combinatorial use of two insertion systems (Cre- and
PhiC31-based) increased the targeted insertion efficiency,
and 4) tandem repeats of recombinase recognition sites in
Figure 2 Targeted insertion in ES cells. (A) Introduction of donor vector (pBDR) harboring promoter-less tdTomato gene into targeted ES cells
(#BDU7) with each expression vector for iCre recombinase, FLPo recombinase or PhiC31 integrase. Red fluorescent ES cells, as analyzed by FACS,
are regarded as successfully targeted tdTomato cassette inserted cells. (B) Co-introduction of combinations of recombinases or integrase expression
vectors increases transgene insertion efficiency.
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insertion of DOI.
Validation of i-PITT
After confirming that desired DNA cassettes can be suc-
cessfully inserted into the landing pads by using recom-
binases and/or integrase in ES cells, a novel seed mouse
line was established using C57BL/6N-derived ES cell
clones harboring the targeted allele. Similar to our previ-
ous seed mouse (TOKMO-1: Rosa26 seed mouse with
mixed genetic background of C57BL/6J and 129/Ola),
both homozygotes and heterozygotes of the new seed
mouse (termed TOKMO-3, line BDT#73) were viable
with normal reproductive ability.
To test PhiC31-based PITT on the new seed mouse
TOKMO-3, we injected various concentrations of PhiC31o
mRNA along with 10 ng/μl of pBER donor vector (similar
to pBDR, without the hygromycin expression cassette) into
fertilized eggs that were generated by in vitro fertilization
(IVF) of C57BL/6N eggs with the epididymal spermatozoa
isolated from a male homozygous TOKMO-3 mouse.
Based on the results (survival rates and targeting efficiency)
presented in Additional file 1: Table S1, we decided to use
7.5 or 15 ng/μl of PhiC31o mRNA in subsequent experi-
ments. These concentrations are relatively higher com-
pared to iCre mRNA concentrations (0.5 or 1.0 ng/μl) that
is typically needed for PITT [11].
The PITT efficiency for Cre- or PhiC31-based systems
was assessed by injecting zygotes, culturing them until
blastocysts, and subsequent analysis for targeted inser-
tion (Figure 3A and B). Targeted insertion was detected
in 28.6% or 16.7% of developed blastocysts (9.0% or 7.6%
of total injected zygotes) when iCre mRNA or PhiC31o
mRNA were injected (Figure 3D). Interestingly, co-injectionof iCre and PhiC31o mRNAs resulted in increased insertion
efficiency of up to 36.8% of developed blastocysts (up to
15.1% of total injected zygotes) (Figure 3D). Notably, inser-
tion rate as high as 61.5% among developed blastocysts was
achieved in a single experiment (Experiment 7 in Additional
file 1: Table S2). Based on these results, we decided to follow
a co-injection strategy using iCre mRNA and PhiC31o
mRNA at concentrations 0.5 ng/μl and 7.5 ng/μl respect-
ively in subsequent experiments.
We next examined whether co-injection of iCre and
PhiC31o mRNAs into zygotes leads to production of tar-
geted Tg fetuses or newborns (Figure 3A and C). Two
different donor vectors were included in the injection,
pBER and pBGO. The targeted insertion efficiencies
were 11.8% (for fetuses) and 25.8% (for newborns), and
2.5% and 4.0% for total injected zygotes, respectively
(Figure 3E).
These results indicate that 1) both PhiC31 and iCre-
based targeted insertions were effective in using the new
seed mouse TOKMO-3, and that 2) combinatorial use of
the two systems enhanced the in vivo targeted insertion
efficiency.
Simultaneous production of multiple different targeted
Tg mouse lines using i-PITT
Given the ability of the original PITT system to insert a
single copy transgene through specially designed donor
vectors, we hypothesized that when a mixture of mul-
tiple donor vectors is injected into zygotes, the resulting
independent Tg founder mouse lines should contain
only one type of transgene from the mixture. If this oc-
curs, more than two types of Tg lines can be produced
at once in a single injection event, which offers versa-
tility to the system and also would reduce the cost
Figure 3 PITT using TOKOM-3 seed mice. (A) Schematic diagram of the PITT injection experiment. Donor vector containing DOI is injected
into the fertilized eggs harboring landing pad together with iCre and/or PhiC31o mRNA. (B) Successful targeted transgenesis in blastocysts
derived from zygotes injected with pBER + iCre mRNA + PhiC31o mRNA. (C) Successful targeted transgenesis in day 13.5 fetuses. Zygotes/fetuses
exhibiting red fluorescence indicate successful targeted insertion of DOI. (D, E) The PITT results in blastocysts (D) and fetuses/pups (E).
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tion method.
As a preliminary test, we first assessed this possibility
by injecting a mixture of donor vectors pBGV, pBGW
and pBDR that confer expression of mCFP, mCitrine
and tdTomato respectively, when they are correctly
inserted. The injection mix containing the three donor
vectors along with iCre and PhiC31o mRNAs wasmicroinjected into the fertilized eggs harboring hemizy-
gous targeted allele (Figure 4A). The injected eggs were
cultured up to blastocyst stage and observed for trans-
gene expression under a fluorescent microscope (Figure 4C).
Among a total of 207 eggs injected in two experimental
days (89 + 118, Experiment 11 and 14 in Additional file 1:
Table S2), 37 eggs developed to blastocysts and 8 of
them showed either green (5 embryos) or red fluorescence
Figure 4 Production of multiple targeted Tg mouse lines using i-PITT. (A) Schematic of simultaneous production of multiple Tg lines using
i-PITT. Multiple donor vectors that harbor different DOI are mixed and co-injected with iCre and PhiC31o mRNA into the fertilized eggs carrying
the i-PITT landing pad in their genome. Appearance of different fluorescent colors indicates successful insertion of DOI. (B) Schematic of targeted
insertion alleles for each DOI. TIex allele 1 is shown as an example. Arrows indicate the PCR primer sets used for genotype identification of the
correct insertion. For detecting targeted transgenesis in blastocyst, 1st PCR was performed using the outer most primer pair sets (black and
blue or black and green or black and red arrows) and nested PCR using the internal primer pair sets (purple arrows). For detecting targeted
transgenesis in fetuses, PCR with only the purple primer pair is sufficient. (C) Example of simultaneous production of multiple targeted Tgs.
Blastocysts (left panel) and day 13.5 fetuses (right panel) derived from injected zygotes. Zygotes/fetuses exhibiting blue, green or red fluorescence
indicate successful insertion of DOI from pBGV, pBGW or pBDR vectors respectively. The results of PCR-based genotyping are shown below the images;
arrows indicate positive samples. (D, E) The results of i-PITT experiment in blastocyst embryos (D) and fetuses/pups (E).
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bryos were non-fluorescent. Nested PCR assay revealed
successfully targeted insertion of DOI in all the 8 blasto-
cysts (Figure 4B and C) with targeted insertion efficiencyof 21.6% injected zygotes that developed into blastocysts
(3.9% of total injected zygotes) (Figure 4D).
Next, we tested whether multiple Tg fetuses or mice
can be obtained simultaneously by co-injecting two or
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PhiC31o mRNAs into zygotes and transferring them to
pseudopregnant recipients (Figure 4A). The microin-
jections were repeated on three separate sessions. As
shown in Figure 4C and E, it was possible to obtain
simultaneously Tg lines derived from donor vectors
containing two to three separate DOI. Targeted inser-
tion efficiency was 25.0% and 17.6% or 28.6% when an-
alyzed at newborn and fetal stages respectively. The
overall targeted Tg rate ranged from 1.8 to 2.2% for
injected zygotes analyzed at both the stages (Figure 4E).
Taken together, the results showed that i-PITT enables
simultaneous production of up to three targeted Tg
lines with different DNA of interest.
Recombination outcomes and genotyping
Theoretically, co-introduction of both iCre and PhiC31o
mRNAs can result in one of several possible insertion al-
leles such as TIex allele 1, 2, 4, 5 and 6 (Figure 1, Additional
file 1: Figure S3 and S4). TIex allele 1 and 2 are the result of
Cre-based recombination or PhiC31-based integration
systems, respectively. Various genotyping assays were
employed to detect targeted insertion of DOI: primer
sets ‘a’, ‘b’, ‘d’ and ‘e’ amplify the 5’ or 3’ junction regions
generated by recombination/integration whereas pri-
mer set ‘c’ amplifies internal regions of the transgene
(Figure 5A). Targeted insertion of DOI generated by
Cre-based recombination only (TIex allele 1) or by
PhiC31 integration system only (TIex allele 2) can be
detected with the primer sets ‘a’ and ‘b’ (for Cre-
mediated recombination) or primer sets ‘a’ and ‘d’ (forFigure 5 PCR-based genotyping. (A) The various possible allele outcome
arrows indicate universal and DOI-specific primers, respectively. The green
insertion for several constructs including pBGX and pBGT. (B) Example of PCR
mixed injection of pBGX and pBGT (see Figure 4E). The primer sets used were
“M274/M376”, “M645/M646”, “M873/M874”, “#235/M026”, “M273/M879”, “M958
“M273/M026”. See text for more details.PhiC31-mediated integration). Since PCR with primer
set ‘a’ is applicable to identification of targeted inser-
tion of DOI performed by either systems, we used
this primer set for the first screening in all i-PITT
experiments.
There are other possible scenarios of Cre and/or
PhiC31 mediated insertions. 1) Combined effect of re-
combination and integration systems can generate an-
other allele (TIex allele 4) as a result of two alternative
sequential events: a) PhiC31 mediated-insertion first
followed by Cre mediated-recombination via lox2272
(Additional file 1: Figure S3), and b) Cre mediated-
insertion first via lox2272 followed by PhiC31 mediated-
recombination (Additional file 1: Figure S4B). This allele
can be distinguished from other alleles by PCR using
primer sets ‘b’, ‘g’ and ‘f (as negative)’ (Figure 5A) or by
sequencing of the PCR-amplified fragments. 2) An-
other possibility is that the inserted DNA may get de-
leted to generate ΔTI allele after two sequential
events: a) PhiC31 mediated-insertion first followed by
Cre mediated-recombination via JT15/JTZ17 (Additional
file 1: Figure S3), and b) Cre mediated-insertion first via
JT15/JTZ17 followed by PhiC31 mediated-recombination
(Additional file 1: Figure S4A). This allele can be detected by
PCR using primer set ‘h’ (Figure 5A).
PCR-genotyping of genomic DNA from i-PITT derived
samples demonstrated that all of the positive F0 fetuses/
pups harbored either TIex allele 1 or 4 (Additional file 1:
Table S2; see offspring No.3 for allele 1 and offspring
No.10 and 11 for allele 4 in Figure 5B). None of posi-
tive F0 fetuses/pups had TIex allele 2 (Additional file 1:s and primer sets (a - i) used for detecting them. The black and blue
arrows indicate semi-universal primers used for identification of targeted
-based genotyping. PCR was performed using 12 samples derived from
as follows (from the top to the bottom): “M273/M839”, “M273/M874”,
/M839”, “M958/M874”, “M953/M839”, “M953/M874”, “M953/M026” and
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changed to be TIex allele 4 immediately after Cre-
mediated recombination via lox2272 (Additional file 1:
Figure S3). We also detected ΔTI allele by PCR using
primer set ‘h’ (2.4% [4/169], Additional file 1: Table S2). In
addition, we performed PCR with primer set ‘i’ for all the
samples showing targeted insertion to detect transgene
mosaicism with respect to the presence of targeted allele
(Figure 5A). As a result, we could detect the transgene
mosaicism in 7 out of 20 (35%) of F0 fetuses/pups
(Additional file 1: Table S2; offspring No.3 individual
in Figure 5B). The results shown in Figure 5B indicated
that offspring No.3, 10 have a targeted fragment de-
rived from pBGT, and offspring No.11 from pBGX.
Offspring No 3 exhibited transgene mosaicism harbor-
ing TIex allele 1, while offspring No.10 and 11 were
pure Tg individuals harboring TIex allele 4.
Reproducibility of i-PITT technology
We next evaluated if the newly developed seed mouse
can be efficiently used in another laboratory to success-
fully perform i-PITT. To test this idea, we suspended
four cauda epididymides dissected from two homozy-
gous seed mice in a 1.2 ml cryotube containing mineral
oil, and shipped the cryotube to RIKEN BioResource
Center (BRC) (Tsukuba, Japan) overnight under refriger-
ated temperatures (Additional file 1: Figure S5A), as de-
scribed by Mochida et al. [12]. At the recipient laboratory,
the epididymal spermatozoa were recovered from the
transported samples and used for IVF with C57BL/6N-
derived oocytes (Additional file 1: Figure S5B) and the
resulting zygotes were subjected to i-PITT. The injection
mix used in the recipient lab was from an experiment con-
ducted at the originating lab (Figure 4E and Experiment
16 in Additional file 1: Table S2) that was shipped under
frozen conditions. Among a total of 170 eggs injected 44
fetuses were recovered and 4 of them were identified as
targeted Tg fetuses with a target insertion efficiency was
9.1% for fetuses recovered and 2.4% for total zygotes
injected (Additional file 1: Figure S5C). This result dem-
onstrates the robustness and reproducibility of the i-PITT
method. Notably, because of this capability of i-PITT
technology, there is no necessity of 1) transportation of
seed mice 2) quarantine housing of the mice at the recipi-
ent facility, 3) re-derivation (cleaning process) of mice, as
may be necessary in some cases, 4) maintenance of seed
mice at the recipient animal facility. This system also en-
ables that multiple different facilities can obtain the cauda
epididymide samples from one central facility.
Discussion
In this study, we designed and generated a new PITT
seed mouse called TOKMO-3 to develop an improved
PITT (i-PITT) system. The landing pad in the new seedmouse constitutes mutant loxP, attP and mutant FRT
sites to enable targeted insertion of transgenes using Cre
or PhiC31 or FLP-based PITT. The seed mouse line is
with the C57BL/6N genetic background and thus the
PITT derived Tg founders under pure genetic back-
ground are immediately available for analysis without
the need for backcrossing. Combinatorial use of Cre-
loxP and PhiC31-attP/B system resulted in improved
targeted insertion efficiency of transgene from the newly
designed donor vectors. The i-PITT strategy also en-
abled simultaneous production of multiple different Tg
mouse lines in a single micro-injection session. The re-
producibility of i-PITT was proven by performing it in
two different laboratories.
In ES cell-based targeted insertion experiments, we
confirmed that both Cre-loxP and PhiC31 systems worked
as expected. The insertion efficiency in both Cre-loxP and
PhiC31 systems was comparable or slightly higher in the
latter than the former. To our knowledge, PITT using
FLP-FRT system has not been developed yet. There are a
few reported mutant FRT sites tested for recombinase-
mediated cassette exchange (RMCE) in cultured cells
[9,13,14]; of these, we included the most newly described
genuine 48-bp variant FRT sites in our system. The tar-
geted recombination efficiency of FLP-FRT system using
mutant FRT sites (F14 and F15) was considerably low
when compared to Cre and PhiC31-based insertion. Not-
ably, Turan et al. [9] who developed F14 and F15 demon-
strated that RMCE employing these mutant FRT sites
worked well when transient assay was performed using
NIH3T3 cells. This implies that targeted insertion by
RMCE with this FRT combination is possible. We found
in this study that the FLP-FRT system failed to cause effi-
cient targeted insertion of DOI (Figure 2A). This may
partly be attributed to the ES cells used in this study and/
or poor transfection efficiency of vectors in those cells. It
remains unclear whether the FLP-FRT system can yield
good in vivo insertion efficiency of DOI. Nevertheless, the
advantages of FLP-FRT system in the i-PITT are, i) it al-
lows removal of extra sequences for generation of the
“clean” inserted allele (TIΔex allele) and ii) combinatorial
use of FLP-FRT and Cre-loxP systems would result in in-
creased targeted insertion frequency of DOI, as described
below (Figure 2B).
The combinatorial use of Cre-loxP and PhiC31 sys-
tems resulted in an increased targeted insertion effi-
ciency in ES cells and in zygotes. While it remains
unclear why simultaneous introduction of the two systems
leads to increased insertion efficiency of DOI, a few pos-
sible scenarios and plausible reasons are discussed here. 1)
Cre-loxP- and PhiC31-based insertions occur independ-
ently and the increased targeted insertion efficiency could
be due to a simple additive effect. 2) Cre-loxP- and
PhiC31-based systems work cooperatively. First insertion
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that generates transient unstable allele (TIex allele 6;
Additional file 1: Figure S4B) which can be subse-
quently converted to either ‘TIex allele 1’ through JT15/
JTZ17 recombination or ‘targeted allele’ through lox2272
by further Cre activity. Alternatively, the unstable TIex al-
lele 6 produced by initial Cre action may be used as a sub-
strate for PhiC31 action to convert the allele to TIex allele
4 (Additional file 1: Figure S4B), which may add synergis-
tic effect to increase the insertion efficiency. Such a co-
operative effect was also observed when Cre-loxP and
FLP-FRT systems are employed together as shown in
Figure 2B. It should be noted that the TIex allele 4 can
be generated not only through “Cre first-PhiC31 next”
recombination/integration event (see Additional file 1:
Figure S4B), but also through “PhiC31 first-Cre next”
event (see Additional file 1: Figure S3). The present
co-injection strategy results in generation of only TIex
allele 1 or 4 (but not TIex allele 2). This presents an-
other advantage of this system, since nearly “clean”
inserted allele lacking the vector can be obtained. On
the other hand, our current donor vector design has a
risk that self-elimination of inserted cassette occurs, lead-
ing to generation of ΔTI allele (see Additional file 1:
Figures S3 and S4A). In fact, we observed the presence
of ΔTI allele in 2.4% of F0 mice (see Additional file 1:
Table S2). Such unwanted outcomes can be avoided by
reversing the order of attB and JTZ17 in the donor
vector, i.e., from “attB-JTZ17” to “JTZ17-attB”. Thus,
we presume that JTZ17-attB architecture in the donor
vector and the employment of tandemly arranged six
copies of JTZ17 (6xJTZ17) can further improve inser-
tion efficiency of DOI to make the i-PITT system even
more efficient.
Although complementary, the i-PITT system provides
advantages to the current state of use of newer nuclease-
mediated genome editing technologies, such as CRISPR/
Cas9, for targeted insertion [15,16]. For example, 1) com-
pared to the use of the well-tested and reliably-used re-
combinase systems, additional development and testing
of CRISPR/Cas9 to generate multiple genetic insertion
events will be necessary to ensure widespread use and
application. 2) The designer nucleases can also intro-
duce un-wanted alleles such as indels along with tar-
geted insertion allele in a mosaic fashion, which often
makes it challenging to identify the desired mutation
by genotyping. On the other hand, i-PITT system gen-
erates only the expected target insertion allele that can
be easily identified by genotyping. 3) Designer nuclease
strategies often require re-constructing of targeting
vectors with significantly longer homology arms that
would occasionally force researchers to compromise
on the size of the inserted cassettes. On the contrary,
the PITT donor vectors readily accept cassettes as highas 10 kb size: these vectors do not require re-designing
and building of special targeting vectors with hom-
ology arms for each project.
Simultaneous injection of multiple donors in separate
sessions resulted in production of as many as three dis-
tinctly targeted Tg mice, each of which contained a
transgene with a single-copy configuration. Notably, the
number of zygotes used was well under 200 in each ses-
sion, while traditional approaches typically use more
than 200 zygotes to generate Tg founders for only one
Tg construct, i-PITT offers over three fold efficiency in
generating Tg founders for multiple transgenes. Thus,
the i-PITT strategy could serve as a high-throughput
and cost-saving method to produce targeted Tg mice.
This is in contrast with the traditional production of Tg
mice which is based on random insertion of multiple
copy numbers of transgenes [2]. Although traditional
transgenesis-based pronuclear injection of DNA contain-
ing multiple transgenes has been used for production of
double or triple Tg mice that contain multiple trans-
genes per animal [17-19], such a strategy is not com-
monly followed due to inherent and obvious problems
that come along with it. Another major pitfall of such
multiple transgene injection strategies using traditional
approaches is that several lines need to be screened to
obtain reliable Tg strains for further work.
The mouse strain C57BL/6N has been considered as
one of the most widely and frequently used strains in
many fields of research [8,20]. Despite the usefulness of
this inbred strain, many random insertion-based Tg lines
are still being generated using mice with mixed genetic
background (e.g. B6D2F2 and B6SJLF2) or FVB/N in-
bred strain because the Tg rate is more efficient and less
difficult with hybrid or FVB/N strains than with C57BL/
6 (e.g. 3.0% for FVB/N, 2.1% for B6D2F1 and 1.2% for
C57BL/6 [% per injected]) [21]. In this study, using the
newly developed i-PITT system in C57BL/6 background,
our Tg production efficiencies ranged from 1.7 to 19.5%.
Unlike the Tg mice generated using traditional approach,
the models generated using TOKMO-3 do not need to
go through extensive and time-consuming steps of back-
crossing. This is particularly useful when the genetic
backgrounds of multiple mutants need to be maintained
in a pure background. For example, tissue-specific Cre
and reporter alleles can be created using TOKMO-3
lines in the correct genetic background as needed for
breeding them with lines produced through global pro-
grams such as the International Knockout Mouse Con-
sortium (IKMC) [8]. Studies have shown that tissue-
specific promoter driven transgenes targeted to specific
sites in the genome are reliably expressed [22-26]. The
usefulness of TOKMO-3 seed mice for generation of
tissue-specific promoter driven transgenes is now under
investigation and has already been verified for some
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seed mouse (data not shown).
For a newly established technology to become widely
usable it should be easily reproducible in other labs and
be flexible. We confirmed the reproducibility and flexi-
bility of i-PITT with the TOKMO-3 mice by performing
it in two different facilities (by different micro-injection
technicians) (see Additional file 1: Figure S5). The flexi-
bility of the i-PITT to use sperm isolation and IVF to
generate zygotes, instead of maintaining a stud male col-
ony for mating with females, was also assessed. Over-
night refrigerated transportation of cauda epididymides
dissected from TOKMO-3 mice [12] were used in an
IVF session with C57BL/6N-derived oocytes at the re-
ceiving end and found to work well. This strategy re-
lieves the requirement to maintain TOKMO-3 mice
colony at the receiving facility, and thus is time- and
cost-saving and convenient. This inter-lab./institution
transportation of refrigerated cauda epididymides has
additional merits over the existing methods of transfer
of frozen embryos/sperm or live individuals [27]. For ex-
ample, the cost of transportation is significantly reduced.
In addition, avoiding transportation of live mice is pref-
erable from an animal welfare point of view [12].
The targeted transgenesis approach using i-PITT en-
ables stable, reliable, predictable, and repeatable transgene
expression which cannot be achieved using traditional
random-insertion transgenesis approaches. The i-PITT
technology described here can generate multiple targeted
Tg models in one-step. The TOKMO-3 mouse and vec-
tors developed in this study will be made available to the
scientific community globally through Experimental
Animal Division of RIKEN BRC (C57BL/6-Gt(ROSA)
26Sor<tm10(PITT)Maoh>, ID: RBRC06517), a part of
Federation of International Mouse Resources- (http://www.
fimre.org/) and also through Tokai University (TOKMO-3
mouse). The plasmid vectors developed in this study are
deposited to Addgene.org. While the i-PITT can be used
for generating any type of transgenic mice, this technology
will be particularly suitable for simultaneously generating
Tg lines for multiple different polymorphic variants or mu-
tant forms of a gene. Considering that individual Tg lines
generated using traditional approaches invariably differ
from each other due to the position effect variation, for the
projects that require generation of multiple different trans-
genes and their comparison with each other, the i-PITT
system offers the perfect solution for such high-throughput
transgene production projects.
Conclusions
Due to the inherent pitfalls that come with mouse random
transgenesis methods, some groups have been developing
newer methods to achieve targeted transgenesis par-
ticularly through direct injection of DNA into zygotes.The new method we report here, termed improved-
PITT (i-PITT), offers many new features compared to
the published targeted transgenesis approaches, in-
cluding the original PITT. The transgenic efficiency
with i-PITT was greatly improved with a typical range
of 10-30%, up to 62%. i-PITT also offers the advantage
of creating multiple Tg models in a single experimental
session and thus serves as an analogous tool for multi-
plexing in Tg technology similar to CRISPR/Cas9 tool
for KO technology. In summary, i-PITT offers i) super-
ior targeting efficiency, ii) multiplexing capability to
insert different cassettes simultaneously, iii) reduction
in the number of animals used; an important animal
welfare consideration, iv) uniform genetic background.




iCre-, PhiC31o- and FLPo-expression plasmids (pAYC,
pBCW and pBCV, respectively) were generated by clon-
ing the PCR-amplified fragment derived from pBOB-
CAG-iCRE-SD (12336, Addgene, Cambridge MA) [28],
pPGKPhiC31obpA (Addgene 13795), and pPGKFLPobpA
(Addgene 13793) [29] into the pCAGGS vector [30],
respectively.
The targeting constructs (pBDT and pBDU) were gen-
erated by modifying the bacterial artificial chromosome
(BAC) clone (RP23-324O18 derived from C57BL/6J)
using recombineering method with the plasmids, pRe-
dET (Gene Bridges GmbH, Heidelberg Germany) [31].
The kanamycin resistant gene, derived from PCR-
amplified fragment from pPGK-neo-loxP (Gene Bridges
GmbH) with primer set, “M753 and M754 (Additional
file 1: Table S3)”, was inserted into the BAC clone by
recombineering. The resulting modified BAC was then
used for retrieving with pAEF-derived retrieval vectors
(pBDD and pBDE), in which the homology regions
were PCR-amplified from the BAC clone or derived
from previously used plasmids (pAHU [HR4 for Rosa26]
and pAHJ [HR3 for Rosa26]) constructed previously by us
[6,32]. The resultant vectors were pBDP and pBDF. The
fragment containing the splicing acceptor, F14, attP, JT15,
eGFP, T2A, neomycin resistant gene, partial human OCT4
gene, polyA, FRT-L, lox2272 and F15, of which a part was
synthesized by GenScript (Piscataway, NJ) was generated
and cloned into pBDP and pBDF, from which the kanamy-
cin resistant gene had been removed. The resulting plas-
mids are designated as pBDT and pBDU, which had been
derived from pBDP and pBDF, respectively. Both the
two plasmids harbor the same long (4732-bp) hom-
ology arms (corresponding to the 3’ region down-
stream of the XbaI site of intron 1 of Rosa26 gene),
but pBDT and pBDU have 1081-bp and 1898-bp short
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stream of the XbaI site of intron 1 of Rosa26 gene), re-
spectively (Additional file 1: Figure S6).
Most of the donor vectors had the following compo-
nents in a 5’ to 3’ direction: which include attB, JTZ17,
F14, DOI, F15, FRT-R, lox2272 and a plasmid backbone
(pIDTSmart Kan), a part of which had been synthesized
by Integrated DNA Technologies (IDT), Inc. (Coraville,
IA). The donor vectors pBFB and pBEZ had tandemly
repeated 6 × JTZ17 (for pBFB) and 6 × attB (for pBEZ)
synthesized by TaKaRa (Kyoto, Japan) in addition to F14,
tdTomato-pA, F15, FRT-R, and lox2272. In the DOI re-
gion, the following cassettes were included in each
donor vector: namely, ‘tdTomato - pA - pA - hygro
(hygromycin B resistance gene) - mouse phosphoglycer-
ate kinase (PGK) promoter’ for pBER, ‘mCitrine - pA’ for
pBGW, ‘tdTomato - pA’ for pBDR, ‘mCFP - pA’ for
pBGV, ‘Dre (derived from custom codon-optimized Dre
synthesized by TaKaRa) - pA’ for pBGX, ‘iRFP - pA’ for
pBGT, and ‘hamster PrP (prion protein) promoter -
rabbit β-globin intron - mouse ferritin heavy chain 1
(mFTH1) - pA’ for pBGO [33-37].
The nucleotide sequences of junctional portions in the
recombinant clones and PCR-amplified fragments were
confirmed by sequencing. These plasmids will be avail-
able to the scientific community through Addgene. The
sequences and features of recombinase/integrase recog-
nition sites are shown in Additional file 1: Table S4.
ES cell targeting, chimera production and establishing of
seed mouse
For in vitro experiments, the linearized targeting vectors,
pBDT and pBDU, were introduced into 129/Ola-derived
E14.1 ES cells by liposomal transfection using Lipofecta-
min 2000 (Invitrogen, Carlsbad, CA). After selection
with G418, the emerging ES cell colonies were picked
and subjected to the PCR-based screening using primer
sets (M024/M195 and M372/M195). The resultant ES
cell clones were designated as #BDT or #BDU and one
of the clones #BDU7, was used for in vitro study as de-
scribed below. To generate TOKMO-3, the linearized
pBDT was introduced into C57BL/6N-derived EGR-101
ES cells by electroporation [38]. After transfection,
G418-resistant ES cell colonies were picked and sub-
jected to the PCR-based screening using primer sets
M024/M195 and M372/M195 for short arm and
M275/M837 for long arm (Additional file 1: Figure S6).
The successfully targeted ES clones were then microin-
jected into the blastocoels of ICR blastocysts to produce
chimeric mice. Germ-line transmission was confirmed for
two ES cell clones (BDT#73 and BDT#78, derived from
EGR-101 ES cells) by crossing the resulting male chimeric
mice to C57BL/6N female mice (data not shown). Further
experiments were performed using offspring of BDT#73line and the homozygous line was established by inter-
crossing heterozygotes. PCR-based genotyping was
performed using primers “M273, M274 and M026”
(Additional file 1: Table S3), which yield 429-bp and
630-bp fragments corresponding to the wild-type al-
lele and targeted alleles, respectively.
Testing for targeted insertion in ES cells
ES cells (2×105: #BDU7 [and E14.1 as a negative con-
trol]) were seeded onto one well of a 6-well plate, with-
out the feeder cells. One day after seeding, transfection
was performed using Lipofectamin 2000 as follows: a
total of 5 μg of circular donor vector(s) containing DOI
was mixed with 5 μg (or without) of circular recombin-
ase/integrase expression plasmids pAYC (iCre), pBCW
(PhiC31) and/or pBCV (FLPo) plasmids. Three days after
transfection, expression of tdTomato-derived fluorescence
in dissociated ES cells was analyzed using FACS LSRFor-
tessa and FlowJo analysis software (Tree Star, Inc.,
Ashland, OR, USA).
Preparation of mRNA
iCre mRNA preparation has been described previously
[11]. Same batch of iCre mRNA that were used in our
previous report was used. We constructed a PhiC31o
mRNA expression plasmid (pBBK) by replacing the
eGFP cDNA in pcDNA3.1EGFP-poly (A83) with the
PhiC31o-coding sequence (derived from pPGKPhiC31obpA)
[29,39]. The pBBK was linearized using XbaI digestion, and
PhiC31o mRNA was then in vitro transcribed using mMES-
SAGE mMACHINE T7 Ultra Kit (Ambion, Austin, TX)
followed by purification of mRNA using MEGAclear Kit
(Ambion). To avoid clogging during microinjection, mRNAs
were filtered by passing through an Ultrafree-MC filter (HV;
0.45 μm in pore size; #UFC30HV00; Millipore, Billerica,
MA) before mixing them with the donor plasmids.
Titration of PhiC31o mRNA concentration
To determine the optimal concentration of PhiC31o
mRNA enabling efficient targeted transgenesis of DOI at
zygote stage, we injected a solution containing various
concentrations (from 0 to 45 ng/μl) of PhiC31o mRNA
and 10 ng/μl of pBER donor vector into fertilized eggs
carrying a heterozygous targeted allele at the Rosa26 locus.
The injected eggs were cultured in KSOM medium cov-
ered with paraffin oil up to blastocyst stage to assess their
survival rate and expression of tdTomato fluorescence.
The results concerning optimization of PhiC31o mRNA
microinjection are compiled in Additional file 1: Table S1.
Microinjection
Donor vector DNA and iCre and/or PhiC31o mRNAs were
mixed in EmbryoMax Injection Buffer (#MR-095-10F;
Millipore). Final concentration (10 ng/μl) of the donor
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and/or PhiC31o mRNA concentrations were altered, de-
pending on the type of experiments. The DNA/mRNA
mixtures were kept at −80°C until use.
Unfertilized oocytes isolated from super-ovulated fe-
male mice (C57BL/6N) were subjected to IVF with
spermatozoa obtained from a homozygous TOKMO-3
male mouse. Microinjection of the DNA/mRNA mixture
was performed both into pronuclei and the cytoplasm of
in vitro fertilized eggs [11]. The injected embryos were
cultured up to blastocyst stage to assess their survival
rate and targeted insertion efficiency or transferred into
the uteri of pseudopregnant ICR females to allow further
development. The resulting fetuses (from days 13.5 to
18.5) or newborn offspring were subjected to genotyping
analysis to assess successful targeted transgenesis.
Preparation and transportation of epididymides
Procedure for inter-laboratory transportation of epididy-
mides was performed according to the method previously
described [12]. Briefly, two adult male homozygotes
(TOKMO-3) were sacrificed to dissect cauda epididy-
mides together with a part of the corpus epididymis and
vas deferens. They were immediately plunged into cryo-
tubes containing cooled mineral oil. The cryotubes were
packed in a plastic bag and kept in a thermos flask con-
taining water at 5-8°C. The samples were then transported
under refrigerated condition from Tokai University
(Kanagawa Prefecture, Japan) to RIKEN BioResource
Center (Ibaraki Prefecture, Japan) using a commercial
courier service that typically takes about 18 h for delivery.
At RIKEN BioResource Center, IVF was performed using
oocytes derived from super-ovulated C57BL/6N female
mice (10-week-old) by incubating spermatozoa recovered
from the delivered epididymides. Fertilized eggs for micro-
injection were obtained via IVF using the spermatozoa
with 65-80% motile activity were used for this experiment.
Detection of targeted transgene insertion
Correct insertion of donor vectors into the Rosa26 locus
was assessed by observing under a fluorescence micro-
scope and/or PCR-based genotyping. The primer sets
were designed to amplify the junctional region generated
by recombination. For detection of targeted insertion of
transgene at blastocysts, genomic DNA from a single
blastocyst was isolated using the PicoPure DNA extraction
kit (#KIT0103; Arcturus, Mountain View, CA) according
to manufacturer’s instructions with the exception that an
embryo was lysed in 10 μl of lysis buffer in a 0.2-mL micro-
tube at 65°C for 3 h and 1 μl lysate was used for nested
PCR. The first round of PCR reaction with the outer pri-
mer pair sets (M022/M338 for pBER and pBDR insertion,
and “M022/M026” for pBGV and pBGW insertion) was
performed using TaKaRa LA-Taq (#RR002A; TaKaRa) in atotal of 10 μl solution. Then, 0.5 μl of the first PCR product
was used as template in a nested PCR with internal
primer pair sets (M273/M879) using TaKaRa Taq (#R001A;
TaKaRa) with 2 × GC buffer I (#9154; TaKaRa) in a total of
10 μl solution.
For detection of targeted insertion of transgene in fe-
tuses and newborns, genomic DNA was isolated from
tail or ear piece using 50 μl of Allele-In-One Mouse Tail
Direct Lysis Buffer (#ABP-PP-MT01500; Allele Biotech-
nology, San Diego, CA). PCR was performed in a total of
10 μl solution containing 2 × GC buffer I, 1 μl of the
crude lysate and the primer pair (M273/M879 for pBER,
pBDR, pBGV, pBGW, pBGX and pBGT, M274/M077 for
pBER, M273/M839 for pBGX, M273/M874 for pBGT,
M274/M376 for pBGX and pBGT, and M273/M955 and
M274/M954 for pBGO) using TaKaRa Taq. We also used
other primer sets (M273/M026 for detection of mosaic
insertion, #235/M026 for detection of TIex allele 2,
M953/M026 for detection of ΔTI allele, M645/M646 for
Dre gene, M873/M874 for iRFP gene, M958/M839 for
TIex allele 1 of pBGX, M958/M874 for TIex allele 1 for
pBGT, M953/M839 for TIex allele 2 or 4 for pBGX and
M953/M874 for TIex allele 2 or 4 for pBGT).
The nucleotide sequences of some PCR-amplified re-
gions were confirmed by sequencing.
Mice
All mice were kept in the Center of Genetic Engineering
for Human Diseases (CGEHD) animal facility at Tokai
University School of Medicine and the RIKEN BioResource
Center. Inbred C57BL/6N and outbred ICR mice were pur-
chased from CLEA Japan Inc. (Tokyo, Japan). The new
seed mice (TOKMO-3) described here were maintained as
homozygotes with an inbred genetic background of
C57BL/6N. Mice are fed ad libitum under 12:12 light
and dark cycle. All the animal experiments were per-
formed in accordance with institutional guidelines and
were approved by The Institutional Animal Care and Use
Committee at Tokai University (Permit Number: #121007,
#132013, #143037) and the RIKEN BioResource Center.
Fluorescent microscopy of blastocysts and fetuses
Expression of fluorescence in blastocysts was inspected
under an Olympus IX70 inverted fluorescence microscope
(Olympus, Tokyo, Japan) with filter sets (U-MNIBA and
U-MWIG). Fluorescence in fetuses was checked using the
Leica M165 FC (Leica, Wetzlar, Germany) with filter sets
for CFP, YFP and red fluorescence.
Additional file
Additional file 1: The following additional data files that contain six
figures (S1-S6) and four Tables (Table S1-S4) are available with the
online version of this paper. Figure S1. Schematic of targeted insertion
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and PhiC31 strategies in ES cells. Figure S3. Schematic of possible out-
comes of co-injection of iCre and PhiC31o mRNAs (“PhiC31 first-Cre next”
scenario). Figure S4. Schematic of possible outcomes of co-injection of iCre
and PhiC31o mRNAs (“Cre first-PhiC31 next” scenario). Figure S5. i-PITT at a
distant laboratory using the new seed mice TOKMO-3. Figure S6. Schematic
of targeting of i-PITT-landing-pad at the Rosa26 locus. Table S1. contains
the optimization of PhiC31o mRNA concentration data and survival rates of
embryos up to blastocyst stage upon injection of PhiC31o mRNA and donor
vector DNA solution. Table S2. contains the results of micro-injection
experiments. Table S3. contains the primers used in the present
study. Table S4. contains the list of recombinase/integrase recognision
sites used in this study.Abbreviations
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